Serious infections in patients with myasthenia gravis: population‐based cohort study

To characterize the frequency and risk of serious infections in patients with myasthenia gravis (MG) relative to age/sex/area‐matched comparators.

[1]  M. Cartwright,et al.  Health maintenance for adults with neuromuscular diseases on immunosuppression , 2019, Muscle & nerve.

[2]  John A. Davis,et al.  Infections and the relationship to treatment in neuromuscular autoimmunity , 2018, Muscle & nerve.

[3]  J. Baddley,et al.  Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question , 2018, Annals of the rheumatic diseases.

[4]  A. Fernández-Codina,et al.  Opportunistic infections in patients with idiopathic inflammatory myopathies , 2018, International journal of rheumatic diseases.

[5]  N. Gilhus,et al.  Myasthenia gravis and infectious disease , 2018, Journal of Neurology.

[6]  Suk-Won Ahn,et al.  The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis , 2017, Journal of clinical neurology.

[7]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[8]  L. Rostaing,et al.  Steroid-Based Therapy and Risk of Infectious Complications , 2016, PLoS medicine.

[9]  I. Petersen,et al.  Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study , 2016, PLoS medicine.

[10]  K. Tu,et al.  Epidemiology of myasthenia gravis in Ontario, Canada , 2016, Neuromuscular Disorders.

[11]  W. Gold,et al.  Reducing the risk of infection in a 74-year-old man who is to receive prednisone , 2014, Canadian Medical Association Journal.

[12]  C. Bombardier,et al.  Serious infections in a population‐based cohort of 86,039 seniors with rheumatoid arthritis , 2013, Arthritis care & research.

[13]  B. Katirji,et al.  Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil , 2012, Journal of Neuroimmunology.

[14]  G. Wolfe,et al.  Myasthenia Gravis , 2012, Seminars in Neurology.

[15]  W. Dixon,et al.  Extended Report , 2022 .

[16]  T. Stukel,et al.  Safety of influenza vaccination in patients with myasthenia gravis: A population‐based study , 2009, Muscle & nerve.

[17]  Teresa To,et al.  Identifying patients with physician-diagnosed asthma in health administrative databases. , 2009, Canadian respiratory journal.

[18]  T. To,et al.  Identifying Individuals with Physcian Diagnosed COPD in Health Administrative Databases , 2009, COPD.

[19]  Karen Tu,et al.  Accuracy of administrative databases in identifying patients with hypertension , 2007, Open medicine : a peer-reviewed, independent, open-access journal.

[20]  Janet E Hux,et al.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.

[21]  S. Yale,et al.  Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. , 1996, Mayo Clinic proceedings.

[22]  R. Lisak,et al.  Infections Occurring in Hospitalized Myasthenia Gravis Patients , 1993, Annals of the New York Academy of Sciences.

[23]  H. Coslett,et al.  Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients , 1984, Annals of neurology.